Results 1 to 10 of about 69,604 (260)

Case Report: Yellow Fever Vaccine-Associated Neurotropic Disease and Associated MRI, EEG, and CSF Findings [PDF]

Frontiers in Neurology, 2022
Yellow fever vaccine-associated neurotropic disease (YEL-AND) is a rare and serious complication following vaccination with the 17D live attenuated yellow fever vaccine.
Michelle Cohen, Madeline Nguyen, Chad D. Nix, Brendan Case, Joshua P. Nickerson, Jacqueline Bernard, Julia Durrant, Delaram Safarpour, Tarvez Tucker, Kamila Vagnerova, William B. Messer, William B. Messer, William B. Messer   +12 more
doaj   +3 more sources

Anterograde transneuronal tracing and genetic control with engineered yellow fever vaccine YFV-17D. [PDF]

Nat Methods, 2021
Transneuronal viruses are powerful tools for tracing neuronal circuits or delivering genes to specific neurons in the brain. While there are multiple retrograde viruses, few anterograde viruses are available.
Li E, Guo J, Oh SJ, Luo Y, Oliveros HC, Du W, Arano R, Kim Y, Chen YT, Eitson J, Lin DT, Li Y, Roberts T, Schoggins JW, Xu W.   +14 more
europepmc   +2 more sources

Yellow fever vaccine [PDF]

BMJ, 2002
Three recently published articles, from Brazil, the United States, and Australia, and three follow up letters from Europe, have challenged the reputation of the yellow fever vaccine, 17D, that for more than 50 years was almost beyond reproach.1–6 These reports describe an illness resembling yellow fever occurring within a week of vaccination for yellow
Philip P. Mortimer
openaire   +4 more sources

Acceptance of yellow fever vaccine in the older traveller: a cohort study. [PDF]

Acta Biomed, 2021
Background and aim: Current demographic changes and improvement of quality of life of elderly population have direct consequences on international travelling. The older traveller demands for specific care and precautions to be observed, as for the yellow
Ferrara P, Masuet-Aumatell C, Ramon-Torrell JM.   +2 more
europepmc   +2 more sources

Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection. [PDF]

NPJ Vaccines, 2020
Yellow fever (YF) virus is a mosquito-borne flavivirus found in Sub-Saharan Africa and tropical South America. The virus causes YF, a viral hemorrhagic fever, which can be prevented by a live-attenuated vaccine, strain 17D. Despite the vaccine being very
Staples JE, Barrett ADT, Wilder-Smith A, Hombach J.   +3 more
europepmc   +3 more sources

A clinician's perspective on yellow fever vaccine-associated neurotropic disease. [PDF]

J Travel Med, 2020
Yellow fever (YF) causes high fever, liver dysfunction, renal failure, hypercoagulopathy and platelet dysfunction and can lead to shock and death with a case-fatality ratio of 20–50%. YF vaccination results in long-lasting protective immunity.
Lecomte E, Laureys G, Verbeke F, Domingo Carrasco C, Van Esbroeck M, Huits R.   +5 more
europepmc   +2 more sources

Disease Resurgence, Production Capability Issues and Safety Concerns in the Context of an Aging Population: Is There a Need for a New Yellow Fever Vaccine?

Vaccines, 2019
Yellow fever is a potentially fatal, mosquito-borne viral disease that appears to be experiencing a resurgence in endemic areas in Africa and South America and spreading to non-endemic areas despite an effective vaccine.
Kay M. Tomashek, Mark Challberg, Seema U. Nayak, Helen F. Schiltz   +3 more
doaj   +2 more sources

Yellow fever vaccine coverage and associated factors among under-five children in Kenya: Data from Kenyan Demographic and Health Survey 2022 [PDF]

Human Vaccines & Immunotherapeutics
Yellow fever is a vaccine preventable hemorrhagic disease that leads to morbidity and mortality in the affected individuals. The only options for preventing and controlling its spread are through vaccination.
Mohammed Seid Ali, Enyew Getaneh Mekonen
doaj   +2 more sources

Repurposing the yellow fever vaccine for intratumoral immunotherapy. [PDF]

EMBO Mol Med, 2020
Live 17D is widely used as a prophylactic vaccine strain for yellow fever virus that induces potent neutralizing humoral and cellular immunity against the wild‐type pathogen.
Aznar MA, Molina C, Teijeira A, Rodriguez I, Azpilikueta A, Garasa S, Sanchez-Paulete AR, Cordeiro L, Etxeberria I, Alvarez M, Rius-Rocabert S, Nistal-Villan E, Berraondo P, Melero I.   +13 more
europepmc   +2 more sources

Safe administration of yellow fever vaccine in patients with suspected egg allergy [PDF]

Journal of Allergy and Clinical Immunology: Global, 2023
Background: The evidence available in the literature on the administration and safety of the yellow fever vaccine in patients with egg allergy is limited.
Fernanda Tormin Tanos Lopes, MSc, Roberta Maia de Castro Romanelli, PhD, Lívia Isabela de Oliveira, BSc, Marcelo Militão Abrantes, PhD, Wilson Rocha, BSc   +4 more
doaj   +2 more sources